Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from IntraCellular rapies

Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022

Looking Into Intra-Cellular Therapies's Return On Capital Employed

Looking Into Intra-Cellular Therapies's Return On Capital Employed

According to Benzinga Pro data, during Q1, Intra-Cellular Therapies (NASDAQ:ITCI) posted sales of $35.00 million. Earnings were up 15.88%, but Intra-Cellular Therapies still reported an overall loss of $72.12 million.

Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating

Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating

Intra-Cellular Therapies shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Recap: Intra-Cellular Therapies Q1 Earnings

Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

What 4 Analyst Ratings Have To Say About Intra-Cellular Therapies

Analysts have provided the following ratings for Intra-Cellular Therapies (NASDAQ:ITCI) within the last quarter:

Organisations

United Parcel Service

Evercore ISI Group

Elevance Health

Canadian National Railway

Schneider National

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play